Table 1.
Patient and tumor baseline characteristics.
| Patient characteristics (n = 107) | |
|---|---|
| Sex | |
| Female | 34 (31.8 %) |
| Male | 73 (68.2 %) |
| Age (y), median (range) | 66 (41–90) |
| Performance score (n = 105) | |
| WHO 0 | 28 (26.7 %) |
| WHO 1 | 55 (52.4 %) |
| WHO 2 | 20 (19.0 %) |
| WHO 3 | 2 (1.9 %) |
| Primary tumor | |
| Lung non-small cell | 72 (67.3 %) |
| Renal cell | 8 (7.5 %) |
| Colorectal | 5 (4.7 %) |
| Hepatocellular | 5 (4.7 %) |
| Lung small-cell | 4 (3.7 %) |
| Melanoma | 4 (3.7 %) |
| Esophageal | 2 (1.9 %) |
| Other | 7 (6.5 %) |
| Tumor stage at initial diagnosis | |
| Stage I | 13 (12.1 %) |
| Stage II | 10 (9.3 %) |
| Stage III | 33 (30.9 %) |
| Stage IV | 51 (47.7 %) |
| Tumor characteristics (n = 114) | |
| Side | |
| Left | 65 (57.0 %) |
| Right | 49 (43.0 %) |
| Max diameter (mm), median (range) | 34 (13–90) |
| Primary tumor controlled | |
| Yes | 94 (82.5 %) |
| No | 20 (17.5 %) |
| Biopsy proven metastasis | |
| Yes | 43 (37.7 %) |
| No | 71 (62.3 %) |
| PET staging performed prior to SABR | |
| Yes | 90 (78.9 %) |
| No | 24(21.1 %) |
| Presentation of adrenal metastasis (as per ESTRO-ASTRO consensus definitions) | |
| Synchronous | 16 (14.0 %) |
| Metachrone oligorecurrence | 44 (38.6 %) |
| Oligoprogression | 53 (46.5 %) |
| Oligopersistance | 1 (0.9 %) |
| Metastatic Pattern | |
| Solitary | 46 (40.4 %) |
| Other Oligometastases (2–5) | 61 (53.5 %) |
| Multiple | 7 (6.1 %) |
| Systemic therapy | |
| Within 3 months | 59 (51.8 %) |
| During/concurrent | 22 (19.3 %) |
| After (>3 mo) | 33 (28.9 %) |